TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

David F McDermott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.